Pluristem Therapeutics Inc. (NASDAQ:PSTI) was the target of unusually large options trading on Tuesday. Stock traders purchased 9,151 call options on the company. This is an increase of approximately 530% compared to the typical daily volume of 1,452 call options.
PSTI traded down $0.32 during trading hours on Tuesday, reaching $6.50. 68,790 shares of the company’s stock traded hands, compared to its average volume of 983,499. The firm has a 50-day moving average price of $7.49 and a 200 day moving average price of $8.90. Pluristem Therapeutics has a 52-week low of $2.82 and a 52-week high of $13.29.
Pluristem Therapeutics (NASDAQ:PSTI) last posted its quarterly earnings results on Sunday, February 7th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.23). Equities analysts anticipate that Pluristem Therapeutics will post -1.09 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of PSTI. ARK Investment Management LLC lifted its stake in shares of Pluristem Therapeutics by 49.2% during the 3rd quarter. ARK Investment Management LLC now owns 1,743,618 shares of the biotechnology company’s stock worth $18,360,000 after purchasing an additional 575,002 shares during the last quarter. Nia Impact Advisors LLC purchased a new stake in shares of Pluristem Therapeutics during the 4th quarter worth $2,122,000. Focused Wealth Management Inc lifted its stake in shares of Pluristem Therapeutics by 583.3% during the 4th quarter. Focused Wealth Management Inc now owns 41,000 shares of the biotechnology company’s stock worth $290,000 after purchasing an additional 35,000 shares during the last quarter. Aristides Capital LLC purchased a new stake in shares of Pluristem Therapeutics during the 3rd quarter worth $330,000. Finally, California Public Employees Retirement System lifted its stake in shares of Pluristem Therapeutics by 167.9% during the 3rd quarter. California Public Employees Retirement System now owns 48,670 shares of the biotechnology company’s stock worth $512,000 after purchasing an additional 30,500 shares during the last quarter. Hedge funds and other institutional investors own 11.95% of the company’s stock.
A number of equities analysts have recently commented on PSTI shares. Zacks Investment Research cut Pluristem Therapeutics from a “hold” rating to a “sell” rating in a report on Friday. Jefferies Financial Group cut Pluristem Therapeutics from a “buy” rating to a “hold” rating and set a $6.00 target price for the company. in a report on Thursday, December 10th. Finally, HC Wainwright reiterated a “buy” rating and issued a $9.00 target price (down previously from $15.50) on shares of Pluristem Therapeutics in a report on Monday, December 7th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $9.25.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.
Featured Story: What is a Reverse Stock Split?
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.